Impact of Advanced Systemic Therapies on Disease Control in AD
Dr. Simpson discusses impact of advanced systemic therapies in AD, and the link between inhibition of type 2 inflammation and reduced IgE levels.
Learning objectives
- Understand the potential of disease modification in AD, with reference to the responses achieved with various approved therapies
- Assess the impact of inhibition of type 2 inflammation and associated comorbidities, and explore as a potential avenue for disease modification
Description
Exploring the concept of disease control in AD. The discussion emphasizes the achievement of significant responses, such as EASI-90, with various approved agents, suggesting progress towards a remitted state. The discussion hovered around the potential of disease modification for sustained control over time. Lastly, the discussion explores the link between type 2 blockade and the reduction in IgE levels, suggesting a potential avenue for disease modification by influencing both the disease and associated comorbidities.
About this expert
Eric Simpson
Professor of Dermatology, School of Medicine, Oregon Health & Science University, Portland, US
See author’s profileRelated resources
